| Prev Close | 69.67 |
| Open | 70.00 |
| Day Low/High | 69.31 / 70.46 |
| 52 Wk Low/High | 56.56 / 73.34 |
| Volume | 7.73M |
Gilead Sciences, Inc. (GILD)
69.56
0.11
0.16
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 1254.38B |
| Market Cap | 86.46B |
| P/E Ratio | 68.31 |
| Div & Yield | N.A. (N.A) |
Takeaways & Observations
This is a great invite, "Wall Street Goes to Washington," in which legendary journalist Michael Wolff will sit down with my pal, The Mooch! And it's free! Happy eighth anniversary, Mr. Market. My Generational Low call on The Kudlow Report was the b...
Takeaways and Observations
"Wishin' and hopin' And thinkin' and prayin'..." -- Dusty Springfield, Wishin' and Hopin' The gap from last week's presidential speech was filled this afternoon. I am more negative than most and more negative than I have been in a while. Liter...
Midday Musings
Nice move off of the lows for Allergan . (More than +$3 for the homegamers!) My Generational Bottom in Bond Yields (last July) looks very much intact. Two basis points higher in yield today Today's three-year US note auction was soft. This is not s...
Takeaways and Observations
Perhaps we can make a parallel between the S&P Index and Snap . Today SNAP just fell (by nearly 15%), maybe the S&P will follow! Hey, a guy can hope. After all, the irrational might now be rationalized. And here is how some hedge fund icons feel ab...
Your Burning Biotech Questions Answered
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
Your Burning Biotech Questions Answered
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
Takeaways and Observations
I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters. I covered last evening's Procter & Gamble short for a profit. "For Traders Only."...
Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This
Some tried-and-true indicators show what's really going on with the market.
Biotech Buoyed by Deal Talk
M&A activity is in a serious upswing, and here are some names to watch.
No Bottoming Signs Yet for Gilead
Don't fight the trend of this stock.
Gilead Has 'Good News' But is it Enough?
Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.
Takeaways and Observations
Fear and doubt seem to have abandoned Wall Street. Dr. Hussman, while very much perma-bear, makes some good points in his weekly market commentary. See boldface. As does my pal Sir Mark Grant on CNBC's Squawk Box. I have reduced my large SPRD G...
5 Toxic Stocks to Avoid
Watch these five stocks very closely in the weeks ahead. You might be able to find a good place to jump out.
Cramer: Here's the Reason for Allergan's Remarkable Run
Static doesn't work in this industry. Pipelines work.
Tesaro, Clovis Oncology Lifting Biotechs
Market are still slightly down across the board as we approach the noon hour. Biotech is hanging in there well despite shellacking Gilead Sciences is taking after ratcheting down guidance. Helping the market is mid-cap concern Tesaro , which is cur...
Stocks Turn Mixed as Oil Prices Rebound, Financials Lag, Disney Gains
Stocks trade mixed as energy shares rebound and financials stocks lag.
Jim Cramer Explains Why Gilead Is a Value Trap
Jim Cramer explains the problem with Gilead's stock.
Scanning the Biotech Universe
Markets are slightly down in the early going. Gilead Science GILD is off about 9% on dismal revenue guidance for 2017 and price target downward revisions at various analyst firms. If 2017 projections do not light a fire under company to use mergers ...
Wake Up Wall Street: European and Asian Shares Trade Higher
This is what you need to know before the opening bell.
Your Pinch Hitter Is Off and Running
I'm glad to be sitting in for Doug Kass on the Daily Diary over the next two days. There is plenty to talk about. Because we are the heart of earnings season, let's start with the quarterly results from two well-known large-cap concerns. It is going...
Gilead Sciences Expects Sales to Decline Sharply
The rest of Gilead's house is in need of serious repair.
My Takeaways and Observations
We are likely in a Trump-centric investment world in 2017. My theme that the president will make market volatility and uncertainty great again, continues. Consider the contrary, Part Deux. Mo' gold and I will accumulate under any weakness go...
The S&P 500 Chart Is Bullish
We could see a healthy pullback and still remain bullish.
My Takeaways and Observations
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
Gilead Sciences Can't Catch a Break
It is difficult to say at what level buyers may show up.
My Takeaways and Observations
The market pushed back presumably after it digested the inaugural speech and absorbed the marches around the world. I don't believe the new president will be market and economy friendly. The reflation trade is in question today. And I remain b...
Buy Stocks You Think Will Survive 'Nuclear Winter'
If you buy right, time and value should do most of the heavy lifting for you.
Biotech Sector to See M&A, Earnings Action
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
4 Biotech Names That Could Be M&A Targets
Animal health and oncology deal activity is heating up in 2017.
